20th October 2021 Repository Corticotropin Injection (Acthar® Gel) for Refractory Severe Noninfectious Keratitis: Efficacy and Safety from a Phase 4, Multicenter, Open-Label Study
15th September 2021 Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTH1-24 Depot and Methylprednisolone in Healthy Subjects
3rd September 2021 Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus
1st June 2021 Topline Patient-Reported Outcome Results from a Multicenter, Open-Label, Phase 4 Study of Repository Corticotropin Injection in Patients with Refractory Severe Noninfectious Keratitis
9th March 2021 Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus
23rd December 2020 Comparison of Steroidogenic Exposure Following the Administration of Repository Corticotropin Injection With a Synthetic ACTH1-24 Depot and Methylprednisolone in Healthy Subjects
26th October 2020 Characterization of the Immunopharmacology of Repository Corticotropin Injection (Acthar® Gel) Compared with Synthetic ACTH1-24 Depot and Methylprednisolone in Healthy Human Subjects
29th September 2020 Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
17th September 2020 Buprenorphine Buccal Film in Patients with Chronic Low Back Pain: A Pooled Subgroup Analysis of Two Double-blind, Placebo-controlled, Randomized Withdrawal Trials by Baseline Pain Severity
5th June 2020 Efficacy and Patient-Reported Outcome Measures from a Two-Part Multicenter, Placebo-Controlled, Randomized Withdrawal Trial